Notch signaling-related therapeutic strategies with novel drugs in neuroblastoma spheroids.

J Pediatr Hematol Oncol

*Suleymaniye Gynecology and Maternity Training and Research Hospital †Department of Histology and Embryology, Istanbul Medical Faculty, Istanbul University, Capa ∥Department of Biochemistry, Faculty of Medicine, Yeni Yuzyil University, Istanbul ‡Department of Pharmacology, Faculty of Medicine, Selcuk University, Konya §Department of Histology and Embryology, Faculty of Medicine, Ege University, Bornova, Izmir, Turkey.

Published: January 2014

Neuroblastoma is a severe pediatric tumor characterized by poor prognosis. Identification of novel molecular targets and diversion of investigations on new drug trials is mandatory for cancer therapy. In this study, vinorelbine tartrate, lithium chloride, clomipramine, and medroxyprogesterone acetate are used for the possible new treatment modalities in neuroblastoma cells. Notch and c-kit are novel molecules in cancer research, and Notch pathway is one of the emerging molecules in the neuroblastoma pathogenesis. Cytotoxic effects of these drugs at different time points, with different doses were studied in the SH-SY5Y human neuroblastoma cell line. Analysis of Notch and c-kit signaling with immunohistochemistry were constituted in multicellular tumor spheroids, and morphologic investigation was performed for digital imaging of cancer stem cells (CSCs) with electron microscopy. Size kinetics of spheroids was also determined after drug treatment. Results showed that all drugs were cytotoxic for neuroblastoma cells. Yet, this cytotoxic action did not correlate with the inhibitory effects in cell signaling. Neuroblastoma spheroids showed increased immunoreactivity of Notch signaling and c-kit. Altered ultrastructural CSCs morphology was observed after clomipramine and medroxyprogesterone acetate treatment compared with other drugs. Lithium chloride showed cellular membrane destruction for both CSCs and the remaining population. In this study, independent effects of cytotoxicity in tumor cells with respect to CSCs were determined. Redundant cells, which are the bulk population in tumor a compound, destroyed with therapy, were neither a target for treatment nor a remarkable investigation of cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0b013e3182755c73DOI Listing

Publication Analysis

Top Keywords

neuroblastoma spheroids
8
lithium chloride
8
clomipramine medroxyprogesterone
8
medroxyprogesterone acetate
8
acetate treatment
8
neuroblastoma cells
8
notch c-kit
8
neuroblastoma
7
notch
5
cells
5

Similar Publications

Combined viral and photodynamic therapy for oncological diseases has great potential to treat aggressive tumors such as glioblastomas. A conjugate of vesicular stomatitis virus (VSV) with protoporphyrin IX was prepared, and its oncolytic effects were studied and compared to the effects of the individual components. The VSV showed an oncolytic effect on glioblastoma cell lines T98G and LN229 at a virus titer of 10 TCID/mL.

View Article and Find Full Text PDF

Integrated Approach to Cyclopiazonic Acid Cytotoxicity Using (2D and 3D Models) and Methods.

Toxins (Basel)

November 2024

Department of Preventive Medicine and Public Health, Food Science, Toxicology and Forensic Medicine, Faculty of Pharmacy and Food Science, University of Valencia, Av. Vicent A Estelles s/n, Burjassot, 46100 Valencia, Spain.

Cyclopiazonic acid (CPA) is an indole-tetramic acid neurotoxin produced by and genera present mainly in fruit, cereals and nuts. This study compares the cytotoxicity produced by CPA after 24, 48 and 72 h of exposure using both monolayers and 3D spheroids in human neuroblastoma SH-SY5Y cells. Furthermore, CPA toxicokinetics was evaluated using models.

View Article and Find Full Text PDF

Neurodegenerative diseases (NDDs) present significant challenges due to limited treatment options, ethical concerns surrounding traditional animal models, and the time-consuming and costly process of using human-induced pluripotent stem cells (iPSCs). We addressed these issues by developing a 3D culture protocol for differentiating SH-SY5Y cells into glutamatergic neurons, enhancing physiological relevance with a 3D microarray culture plate. Our protocol optimized serum concentration and incorporated retinoic acid (RA) to improve differentiation.

View Article and Find Full Text PDF

Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth.

Pharmaceuticals (Basel)

October 2024

Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, New York, NY 11439, USA.

Dysregulation of receptor tyrosine kinase c-MET is known to promote tumor development by stimulating oncogenic signaling pathways in different cancers, including pediatric neuroblastoma (NB). NB is an extracranial solid pediatric cancer that accounts for almost 15% of all pediatric cancer-related deaths, with less than a 50% long-term survival rate. In this study, we analyzed a large cohort of primary NB patient data and revealed that high expression strongly correlates with poor overall survival, disease progression, relapse, and high levels in NB patients.

View Article and Find Full Text PDF

Targeted Gold Nanoclusters for Synergistic High-Risk Neuroblastoma Therapy through Noncanonical Ferroptosis.

ACS Appl Mater Interfaces

October 2024

Department of Chemistry, College of Chemistry and Life Science, Center of Excellence for Environmental Safety and Biological Effects, Beijing University of Technology, Beijing 100124, China.

Article Synopsis
  • * Researchers have developed a gold nanocluster (NANT) that targets neuroblastoma cells and enhances sensitivity to ferroptosis, a different form of cell death.
  • * NANT promotes noncanonical ferroptosis by increasing iron levels in the tumor and has shown effective growth inhibition in tumor models while being safe for heart health.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!